Literature DB >> 25484288

ACE2 deficiency shifts energy metabolism towards glucose utilization.

Stella Bernardi1, Christos Tikellis2, Riccardo Candido3, Despina Tsorotes4, Raelene J Pickering5, Fleur Bossi6, Renzo Carretta7, Bruno Fabris8, Mark E Cooper9, Merlin C Thomas10.   

Abstract

BACKGROUND: This study aimed at investigating the effects of genetic angiotensin-converting enzyme (ACE) 2 deficiency on glucose homeostasis in the pancreas and skeletal muscle and their reversibility following ACE inhibition. PROCEDURES: ACE2-knockout and C57bl6J mice were placed on a standard diet (SD) or a high-fat diet (HFD) for 12 weeks. An additional group of ACE2-knockout mice was fed a SD and treated with the ACE inhibitor, perindopril (2 mg kg(-1)day(-1)). Glucose and insulin tolerance tests, indirect calorimetry measurements and EchoMRI were performed. Non-esterfied 'free' fatty acid oxidation rate in skeletal muscle was calculated by measuring the palmitate oxidation rate. β-cell mass was determined by immunostaining. Insulin, collectrin, glucose transporter protein, and peroxisome proliferator-activated receptor-γ expression were analysed by RT-PCR. Markers of mithocondrial biogenesis/content were also evaluated. MAIN
FINDINGS: ACE2-knockout mice showed a β-cell defect associated with low insulin and collectrin levels and reduced compensatory hypertrophy in response to a HFD, which were not reversed by perindopril. On the other hand, ACE2 deficiency shifted energy metabolism towards glucose utilization, as it increased the respiratory exchange ratio, reduced palmitate oxidation and PCG-1α expression in the skeletal muscle, where it up-regulated glucose transport proteins. Treatment of ACE2-knockout mice with perindopril reversed the skeletal muscle changes, suggesting that these were dependent on Angiotensin II (Ang II). PRINCIPAL
CONCLUSIONS: ACE2-knockout mice display a β-cell defect, which does not seem to be dependent on Ang II but may reflect the collectrin-like action of ACE2. This defect seemed to be compensated by the fact that ACE2-knockout mice shifted their energy consumption towards glucose utilisation via Ang II.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin-converting enzyme 2; Collectrin; High-fat diet; Pancreas; Skeletal muscle

Mesh:

Substances:

Year:  2014        PMID: 25484288     DOI: 10.1016/j.metabol.2014.11.004

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

1.  Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice.

Authors:  María José Soler; Marta Riera; Heleia Roca-Ho; Vanesa Palau; Javier Gimeno; Julio Pascual
Journal:  Lab Invest       Date:  2020-05-29       Impact factor: 5.662

2.  High-fat diet-induced glucose dysregulation is independent of changes in islet ACE2 in mice.

Authors:  Harshita Chodavarapu; Kavaljit H Chhabra; Huijing Xia; Vinayak Shenoy; Xinping Yue; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-02       Impact factor: 3.619

3.  Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Authors:  Qi Cheng; Nishank Shah; Angelika Bröer; Stephen Fairweather; Yang Jiang; Dieter Schmoll; Ben Corry; Stefan Bröer
Journal:  Br J Pharmacol       Date:  2017-02-14       Impact factor: 8.739

4.  Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.

Authors:  Nicholas Cauwenberghs; Mary Prunicki; František Sabovčik; Dalia Perelman; Kévin Contrepois; Xiao Li; Michael P Snyder; Kari C Nadeau; Tatiana Kuznetsova; Francois Haddad; Christopher D Gardner
Journal:  Am J Clin Nutr       Date:  2021-11-08       Impact factor: 8.472

5.  Mitochondrial dysfunction is associated with lipid metabolism disorder and upregulation of angiotensin-converting enzyme 2.

Authors:  Qian Zhao; Xiaoshan Zhou; Raoul Kuiper; Sophie Curbo; Anna Karlsson
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

6.  ACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice.

Authors:  Robin Shoemaker; Frederique Yiannikouris; Sean Thatcher; Lisa Cassis
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-08-04       Impact factor: 4.310

7.  Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control.

Authors:  Yang Jiang; Adam J Rose; Tjeerd P Sijmonsma; Angelika Bröer; Anja Pfenninger; Stephan Herzig; Dieter Schmoll; Stefan Bröer
Journal:  Mol Metab       Date:  2015-02-16       Impact factor: 7.422

Review 8.  TRAIL modulates the immune system and protects against the development of diabetes.

Authors:  Fleur Bossi; Stella Bernardi; Giorgio Zauli; Paola Secchiero; Bruno Fabris
Journal:  J Immunol Res       Date:  2015-02-18       Impact factor: 4.818

9.  Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System.

Authors:  Barbara Toffoli; Bruno Fabris; Giacomo Bartelloni; Fleur Bossi; Stella Bernardi
Journal:  Mediators Inflamm       Date:  2016-12-14       Impact factor: 4.711

10.  Dynamics of ADAM17-Mediated Shedding of ACE2 Applied to Pancreatic Islets of Male db/db Mice.

Authors:  Kim Brint Pedersen; Harshita Chodavarapu; Constance Porretta; Leonie K Robinson; Eric Lazartigues
Journal:  Endocrinology       Date:  2015-10-06       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.